Tech Company Financing Transactions
eXmoor pharma Funding Round
On 5/30/2023, eXmoor pharma secured $35 million in Series A funding from Kineticos Ventures and MVM Life Science Partners.
Transaction Overview
Company Name
Announced On
5/30/2023
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to launch its Cell and Gene Therapy Centre, a 65,000 sq ft GMP manufacturing facility, purpose-built to develop and manufacture autologous and allogeneic cell therapies, as well as viral vectors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Future Space, North Gate (UWE) Filton Road, Stoke Gifford
Bristol, BS34 8RB
UK
Bristol, BS34 8RB
UK
Phone
Undisclosed
Website
Email Address
Overview
eXmoor pharma is a one-stop cell and gene therapy partner accelerating the manufacturing journey from research to patients. Founded in 2004, eXmoor has specialized in the CGT sector since 2007 helping organisations to understand, plan and implement the appropriate CMC strategy. eXmoor does this via its translational and capital consulting groups, process and analytical development labs and now GMP manufacturing capability. eXmoor has completed over 500 projects for 150 clients and is headquartered in Bristol, UK, with 70 current employees, growing to 200 by 2027.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Angela Osborne
Chief Technical Officer
Lucy Foley
Browse more venture capital transactions:
Prev: 5/30/2023: Carrum Health venture capital transaction
Next: 5/30/2023: UnifyWork venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs